Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a report released on Monday, Benzinga reports. They presently have a $15.00 price target on the stock. Wedbush’s target price would suggest a potential upside of 189.58% from the company’s previous close.
Several other research firms have also issued reports on INZY. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Inozyme Pharma in a research report on Thursday, August 8th. Stifel Nicolaus assumed coverage on Inozyme Pharma in a report on Thursday, September 12th. They issued a “buy” rating and a $16.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a research report on Tuesday, August 6th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $17.00 price target (up previously from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $16.14.
Read Our Latest Analysis on Inozyme Pharma
Inozyme Pharma Trading Up 0.8 %
Inozyme Pharma (NASDAQ:INZY – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). On average, sell-side analysts expect that Inozyme Pharma will post -1.68 earnings per share for the current fiscal year.
Institutional Trading of Inozyme Pharma
Hedge funds and other institutional investors have recently modified their holdings of the business. Samlyn Capital LLC raised its position in Inozyme Pharma by 15.0% during the second quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock valued at $14,943,000 after buying an additional 437,622 shares during the period. Eventide Asset Management LLC increased its holdings in shares of Inozyme Pharma by 1.8% in the 4th quarter. Eventide Asset Management LLC now owns 3,179,837 shares of the company’s stock valued at $13,546,000 after purchasing an additional 54,837 shares during the period. Affinity Asset Advisors LLC lifted its position in shares of Inozyme Pharma by 8.1% in the second quarter. Affinity Asset Advisors LLC now owns 2,856,252 shares of the company’s stock worth $12,739,000 after purchasing an additional 213,733 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Inozyme Pharma by 1.4% during the first quarter. Vanguard Group Inc. now owns 2,419,020 shares of the company’s stock worth $18,530,000 after purchasing an additional 33,998 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Inozyme Pharma by 154.1% during the second quarter. Millennium Management LLC now owns 1,787,947 shares of the company’s stock worth $7,974,000 after purchasing an additional 1,084,341 shares during the period. Institutional investors and hedge funds own 88.30% of the company’s stock.
About Inozyme Pharma
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
Read More
- Five stocks we like better than Inozyme Pharma
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 Multi-Bagger Stocks to Buy Now for Explosive Growth
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Capricor Therapeutics is up over 100%, Could Rise Even Higher
- Are Penny Stocks a Good Fit for Your Portfolio?
- Citi Analysts Turn More Bullish on Walmart Stock: Time to Buy?
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.